CTIX, el lunes participa en la Rodman&Rendshaw Investmen Conference.....
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that it will be a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Cellceutix will be presenting on Monday, September 9 at 2:00 PM EDT. The conference is being held at the Millennium Broadway Hotel in New York City from September 8 - September 10.
"We are very pleased to once again be presenting at the Rodman and Renshaw annual investment conference," said Leo Ehrlich, chief executive officer at Cellceutix. "In a live webcast for institutional and other investors, we will be providing the current status of the clinical trials of our anti-cancer drug, Kevetrin™, hosted at Harvard's Dana-Farber Cancer Institute as well as an update on the impending clinical trial of our anti-psoriasis drug, Prurisol, and other corporate developments. Our presentation last year was extremely well received and we hope that this year's corporate update will have a similar response."